Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 1;35(7-8):495–511. doi: 10.1101/gad.348221.120

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Driskill et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Figure 2. — TAZ-CAMTA1 is required for tumor progression and maintenance. (A) Schematic for removal of TAZ-CAMTA1 transgene expression after tumor formation. (B) Survival curve for mice that were maintained on doxycycline water (median survival = undefined, n = 6) or normal water (median survival = 16 d, n = 5) after P40. (**) P < 0.01, Mantel-Cox test. (C–H) H&E (C–E) and CD31 immunostaining (F–H) of Ctrl (C,F), TAZ-CAMTA1^iEC (D,G), and TAZ-CAMTA1^iEC mice given doxycycline for 2 wk (E,H). All P40 TAZ-CAMTA1^iEC mice (n = 5) exhibited tumors, while no P40 Ctrl mice (n = 5) or P54 TAZ-CAMTA1^iEC mice (receiving 2 wk of doxycycline after P40, n = 3) had any lung tumors. Black arrows point to examples of tumors within blood vessels. Scale bar, 50 µm. (I) Quantification of tumors observed per 40× field of view in P40 Ctrl (0 ± 0, n = 5), P40 TAZ-CAMTA1^iEC (2.5 ± 0.7, n = 5, [**] P = 0.01), P54 Ctrl (0 ± 0, n = 3), or P54 TAZ-CAMTA1^iEC mice (0 ± 0, n = 3, P > 0.05). (J) Quantification of noncapillary vessels affected in P40 Ctrl (0% ± 0, n = 5), P40 TAZ-CAMTA1^iEC (51.3% ± 8.9, n = 5, [***] P < 0.001), P54 Ctrl (0% ± 0, n = 3), or P54 TAZ-CAMTA1^iEC mice (0% ± 0, n = 3, P > 0.05). (K) Quantification of independent tumors observed per vessel in P40 Ctr (0 ± 0, n = 5), P40 TAZ-CAMTA1^iEC (2.1 ± 0.3, n = 5, [****] P < 0.0001), P54 Ctrl (0 ± 0, n = 3), or P54 TAZ-CAMTA1^iEC mice (0 ± 0, n = 3, P > 0.05). (L–N) Endomucin (Emcn) and Ki67 immunofluorescence of P40 and P54 TAZ-CAMTA1^iEC vessels. P40 TAZ-CAMTA1^iEC (14.4 ± 2.6, n = 3) vessels had significantly more Ki67 positivity than Ctrl (1.8 ± 0.2, n = 3, [**] P < 0.01), while P54 TAZ-CAMTA1^iEC (1.4 ± 1.4, n = 3) vessels had no difference in Ki67 positivity compared with control (0.8 ± 0.8, n = 3, P > 0.05). White arrows point to Ki67⁺Emcn⁺ endothelial cells. Scale bars, 25 µm. All data are presented as mean ± S.E.M, and P-values were calculated with unpaired t-tests.